Encyclopedia / Pharmaceutical / Pharmaceutical Intermediates / Organic Intermediate

Alendronate sodium

CAS：121268-17-5
MW:325.122
MF：C4H18NNaO10P2

Alendronate sodium, with the chemical formula C4H12NNaO7P2 and CAS registry number 121268-17-5, is a compound used in the treatment and prevention of osteoporosis. It belongs to a class of drugs known as bisphosphonates, which work by inhibiting the activity of osteoclasts, cells responsible for bone resorption. Alendronate sodium is available in oral tablet form and is typically taken once a week. Common side effects include gastrointestinal disturbances, such as abdominal pain and heartburn. It is important to take alendronate sodium with a full glass of water and remain upright for at least 30 minutes after taking the medication to prevent esophageal irritation. Alendronate sodium is a widely prescribed medication for the management of osteoporosis and has been shown to reduce the risk of fractures in postmenopausal women and men with osteoporosis.

View more+

Email Tweet Share

Names and ldentifier
Properties
Use and Manufacturing
Safety and Handling
Msds
Other Information
Computational chemical data
Related Questions
Realated Product Infomation

1. Names and Identifiers

1.1 Name: Alendronate sodium

1.2 Synonyms: (4-Amino-1-hydroxy-1,1-butanediyl)bis(phosphonic acid) trihydrate; (4-Amino-1-hydroxy-1-phosphonobutyl)phosphonic Acid Monosodium Salt Trihydrate; 4-amino-1-hydroxy-1-phosphonobutyl phosphonic acid, monosodium, MK-217; 4-amino-1-hydroxy-1-phosphonobutyl phosphonic acid,monosodium MK-217; 4-amino-1-hydroxy-1-phosphonobutyl phosphonic acid,monosodium,Alendronate sodium trihydrate; Adronat; Alendronate trihydrate sodium; Alendronate (sodium hydrate); Alendronate monosodium trihydrate; Alendronate Sodium (200 mg); alendronate sodium hydrate; Alendronate sodium trihydrate; alendronate trihydrate; Alendronic acid monosodium salt trihydrate; Dronal; Fosamsx; G-704650; hydrogène (4-amino-1-hydroxy-1-phosphonobutyl)phosphonate de sodium trihydrate; MFCD01748233; Monosodium (4-Amino-1-hydroxy-1-phosphonobutyl)phosphonate Trihydrate; MonosodiuM Alendronate Trihydrate; Natriumhydrogen-(4-amino-1-hydroxy-1-phosphonobutyl)phosphonattrihydrat; onclast; P,P'-(4-Amino-1-hydroxybutylidene)bis-phosphonicacidmonosodiumsalt; Phosphonic acid, (4-amino-1-hydroxybutylidene)bis-, hydrate (1:3); Phosphonic acid, (4-amino-1-hydroxybutylidene)bis-, sodium salt, hydrate (1:1:3); Sodium alendronate; Sodium Alendronate Trihydrate; SodiuM Alendronate, EP; Sodium hydrogen (4-amino-1-hydroxy-1-phosphonobutyl)phosphonate hydrate (1:1:3);

View all

1.3 CAS No.: 121268-17-5

1.4 CID: 23681107

1.5 EINECS: 601-766-4

1.6 Molecular Formula: C4H18NNaO10P2

1.7 Inchi: InChI=1S/C4H13NO7P2.Na.3H2O/c5-3-1-2-4(6,13(7,8)9)14(10,11)12;;;;/h6H,1-3,5H2,(H2,7,8,9)(H2,10,11,12);;3*1H2/q;+1;;;/p-1

1.8 InChkey: DCSBSVSZJRSITC-UHFFFAOYSA-M

1.9 Canonical Smiles: C(CC(O)(P(=O)(O)O)P(=O)(O)[O-])CN.O.O.O.[Na+]

1.10 Isomers Smiles: C(CC(O)(P(=O)(O)O)P(=O)(O)[O-])CN.O.O.O.[Na+]

2. Properties

2.1 Solubility: water, double-distilled: 10?mg/mL

2.2 Appearance: White Crystalline Solid

2.3 Storage: ?20°C

2.4 Chemical Properties: White Crystalline Solid

2.5 Color/Form: white

2.6 Water Solubility: water, double-distilled: 10 mg/mL soluble in water at 10mg/ml

2.7 Stability: Store in freezer

2.8 StorageTemp: -20°C

3. Use and Manufacturing

3.1 Definition: ChEBI: A hydride that is the trihydrate of alendronate sodium

3.2 Description

Alendronate sodium is a chemical compound with the CAS number 121268-17-5. It is a white, crystalline powder with no distinct odor. The molecular formula of alendronate sodium is C4H12NNaO7P2. It is highly soluble in water. In terms of safety information, alendronate sodium may cause irritation to the eyes, skin, and respiratory system. It is important to handle this compound with care and use appropriate protective measures.

Applicable Fields

Osteoporosis Treatment: Alendronate sodium is primarily used in the field of osteoporosis treatment. Its mechanism of action involves inhibiting the activity of osteoclasts, which are cells responsible for bone resorption. By reducing bone resorption, alendronate sodium helps to increase bone density and prevent fractures in individuals with osteoporosis.

Storage

Conditions: Store in a cool and dry place.

View all

3.3 GHS Classification: Signal: Danger
GHS Hazard Statements
Aggregated GHS information provided by 71 companies from 10 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

Reported as not meeting GHS hazard criteria by 2 of 71 companies. For more detailed information, please visit ECHA C&L website

Of the 9 notification(s) provided by 69 of 71 companies with hazard statement code(s):

H302 (100%): Harmful if swallowed [Warning Acute toxicity, oral]
H315 (60.87%): Causes skin irritation [Warning Skin corrosion/irritation]
H318 (55.07%): Causes serious eye damage [Danger Serious eye damage/eye irritation]
H335 (62.32%): May cause respiratory irritation [Warning Specific target organ toxicity, single exposure; Respiratory tract irritation]
H361 (49.28%): Suspected of damaging fertility or the unborn child [Warning Reproductive toxicity]
H373 (50.72%): Causes damage to organs through prolonged or repeated exposure [Warning Specific target organ toxicity, repeated exposure]

Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown.

Precautionary Statement Codes
P201, P202, P260, P261, P264, P270, P271, P280, P281, P301+P312, P302+P352, P304+P340, P305+P351+P338, P308+P313, P310, P312, P314, P321, P330, P332+P313, P362, P403+P233, P405, and P501

View all

3.4 Methods of Manufacturing: All chemicals were commercially purchased from Sigma Aldrich and used without further purification. Sodium carbonate, NaPreparation of alendronic acid monosodium salt; A mixture of 4-amino-butyric acid (10. Og, 0.097mol) and phosphorous acid (15.9g, 0.194mol) in acetonitrile (150ml) was heated at a temperature of 55-65°C and phosphorous trichloride (26.6g, 0.194mol) was added slowly under stirring. After completion of the addition, the reaction temperature was raised to 70-75Step 1: A mixture of 4-amino-butyric acid (10.0 g, 0.097 mol) and phosphorous acid (15.9 g, 0.194 mol) in acetonitrile (150 ml) was heated at a temperature of 55-65° C. and phosphorous trichloride (26.6 g, 0.194 mol) was added slowly under stirring. After completion of the addition, the reaction temperature was raised to 70-75° C. and the reaction continued for 6-9 hours at the same temperature. The reaction mixture was cooled to 60-65° C. and water (150 ml) was added slowly at the same temperature. The reaction temperature was then increased to 90-100° C. and maintained for the next 4-6 hours. The reaction mixture was then cooled to 55-65° C. and the reaction mixture pH was adjusted to 4.4-4.8 with sodium hydroxide solution. The reaction mixture was cooled to 25-35° C. and the aqueous layer containing the product was separated from the upper acetonitrile layer. The aqueous layer was cooled to and maintained at 0-5° C. for 3 hours. The solid product was separated by filtration and washed with water and finally with methanol to obtain sodium alendronate. The product was dried in a vacuum oven at 45-50° C. until loss on drying was less than 0.5percent w/w. Yield: 16 g (69.6percent). Appearance: almost white powder. Melting range: 234-238° C. (with decomposition).2.6 g (0.025 mol) of -γaminobutyric acid and 6.2 g (0.075mol) of phosphorous acid was added into 6.8 mL of MSA on stirring. Then 7.0 mL (0.075 mol) of phosphoryl chloride was added dropwise in ca. 15 min, and the contents of the flask were stirred at 75°C for 12 h. After cooling the mixture to 26°C, 19 mL (1.1 mol) of water was added and the mixture was stirred further at 105°C for 4 h. The pH was adjusted to 1.8 by adding ~12 mL of 50percent aqueous sodium hydroxide to the mixture. Then, the mixture was stirred at room temperature for 2 h and the precipitate was removed by filtration. The crude product was suspended in 50 mL ofwater and the mixture was stirred at 100°C for 1 h, then the pH was adjusted to 4, 5. After cooling the mixture to 26°C, the solid product was filtered off to give 5.0 g (60percent) of sodium alendronate trihydrate (8) in a purity of 97percent.3.8 mmol (1 equiv) of the respective carboxylic acid (658 mg 3-pyridylacetic acid hydrochloride for 1, 478 mg imidazol-1-yl-acetic acid for 2, 339 mg β-alanine for 3, 392 mg γ-aminobutyric acid for 4, 499 mg 6-aminohexanoic acid for 5) were added to 11.4 mmol (3 equiv) HTo a 250 ml reaction vessel equipped with a water condenser, 8.5 gm (0.1 mol) pyrrolidone, and 33.5 ml water was added under nitrogen atmosphere. Then, 17.2 gm (0.125 mol) PCl To a 250 ml reaction vessel equipped with water condenser, 8.5 gm (0.1 mol) pyrrolidone, and 33.5 ml water was added under nitrogen atmosphere. Then 17.2 gm (0.125 mol) PCl In a 250 reaction vessel equipped with water condenser, 8.5 gm (0.1 mol) pyrrolidone, 14 ml water and 11.5 gm methane sulphonic acid was added under nitrogen atmosphere. At room temperature 17.2 gm (11 ml, 0.125 mol) PClIn a 250 reaction vessel equipped with a water condenser, 8.5 gm (0.1 mol) pyrrolidone, 14 ml water, and 11.5 gm methane sulphonic acid were added under a nitrogen atmosphere. At room temperature, 17.2 gm (11 ml, 0.125 mol) PClExample 3 In a reaction vessel, 17.0 g(0.2 mol) pyrrolidone, 22 ml water and 23 gm methane sulphonic acid were taken and was heated to reflux (105 °C) for 9 hours or till the disappearance of pyrrolidone (monitored by TLC method). The mass was cooled to room temperature and PCl3 (17.5 ml, 0.199 mol) was added drop-wise while maintaining the temperature below 65 °C. Further the reaction was stirred at 60-65 °C for 30 minutes and then the temperature was raised to 110 °C, water was continuously distilled under vacuum. The mass was then cooled to 60 °C and added a further quantity of 90.39 gm (57.5 ml, 0.6565 mol) PCl3 was added drop-wise while maintaining the temperature below 60 °C followed by 25.5 ml of HEXAMPLE 3 In a reaction vessel, 17.0 g (0.2 mol) pyrrolidone, 22 ml water, and 23 gm methane sulphonic acid were mixed and then heated to reflux (i.e., 105° C.) for 9 hours or till the disappearance of pyrrolidone was observed (monitored by TLC method). The mass was then cooled to room temperature and PCl

View all

3.5 Usage: A bisphosphonate used as a bone reabsoption inhibitor

4. Safety and Handling

4.1 Safety: A poison by intravenous route. Experimental reproductive effects. When heated to decomposition it emits toxic vapors of NO_x, PO_x, and NaO.
Hazard Codes:?Xn,Xi
The Risk Statements:
22:? Harmful if swallowed?
36/37/38:? Irritating to eyes, respiratory system and skin
The Safety Statements:
26:? In case of contact with eyes, rinse immediately with plenty of water and seek medical advice?
36:? Wear suitable protective clothing??
WGK Germany: 3

View all

4.2 Specification: ?Alendronate sodium , its cas register number is 121268-17-5. It also can be called Fosamax ; Monosodium alendronate ; Alendronic acid monosodium salt ; Fosalan ; Alendros ; Bifosa ; NeoBon ; 4-Amino-1-hydroxybutylidene-1,1-bisphosphonic acid monosodium salt ; and Osteovan .?It is marketed alone as well as in combination with vitamin D, and Merck's U.S. patent on alendronate expired in 2008 and Merck lost a series of appeals to block a generic version of the drug from being certified by the U.S. Food and Drug Administration (FDA).?Alendronate inhibits osteoclast-mediated bone-resorption.

View all

4.3 Toxicity

1.	???	ivn-rat LDLo:30?mg/kg	???	KSRNAM ?? Kiso to Rinsho. Clinical Report. 28 (1994),3229.
2.	???	ivn-dog LDLo:10?mg/kg	???	KSRNAM ?? Kiso to Rinsho. Clinical Report. 28 (1994),3229.

View all

5. MSDS

2.Hazard identification

2.1 Classification of the substance or mixture

Acute toxicity - Oral, Category 4

Skin irritation, Category 2

Serious eye damage, Category 1

Specific target organ toxicity \u2013 single exposure, Category 3

Reproductive toxicity, Category 2

Specific target organ toxicity \u2013 repeated exposure, Category 2

Hazardous to the aquatic environment, long-term (Chronic) - Category Chronic 3

2.2 GHS label elements, including precautionary statements

Pictogram(s)
Signal word	Danger
Hazard statement(s)	H302 Harmful if swallowed H315 Causes skin irritation H318 Causes serious eye damage H335 May cause respiratory irritation H361 Suspected of damaging fertility or the unborn child H373 May cause damage to organs through prolonged or repeated exposure H412 Harmful to aquatic life with long lasting effects
Precautionary statement(s)
Prevention	P264 Wash ... thoroughly after handling. P270 Do not eat, drink or smoke when using this product. P280 Wear protective gloves/protective clothing/eye protection/face protection. P261 Avoid breathing dust/fume/gas/mist/vapours/spray. P271 Use only outdoors or in a well-ventilated area. P201 Obtain special instructions before use. P202 Do not handle until all safety precautions have been read and understood. P260 Do not breathe dust/fume/gas/mist/vapours/spray. P273 Avoid release to the environment.
Response	P301+P312 IF SWALLOWED: Call a POISON CENTER/doctor/\u2026if you feel unwell. P330 Rinse mouth. P302+P352 IF ON SKIN: Wash with plenty of water/... P321 Specific treatment (see ... on this label). P332+P313 If skin irritation occurs: Get medical advice/attention. P362+P364 Take off contaminated clothing and wash it before reuse. P305+P351+P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. P310 Immediately call a POISON CENTER/doctor/\u2026 P304+P340 IF INHALED: Remove person to fresh air and keep comfortable for breathing. P312 Call a POISON CENTER/doctor/\u2026if you feel unwell. P308+P313 IF exposed or concerned: Get medical advice/ attention. P314 Get medical advice/attention if you feel unwell.
Storage	P403+P233 Store in a well-ventilated place. Keep container tightly closed. P405 Store locked up.
Disposal	P501 Dispose of contents/container to ...

2.3 Other hazards which do not result in classification

none

View all

6. Synthesis Route

121268-17-5Total: 5 Synthesis Route

56-12-2 388 Suppliers

121268-17-5 337 Suppliers

616-45-5

121268-17-5 337 Suppliers

View all

7. Precursor and Product

precursor:

616-45-5

56-12-2

66376-36-1

183959-44-6

1310-73-2

product:

66376-36-1

8. Computed Properties

Molecular Weight：325.122g/mol
Molecular Formula：C₄H₁₈NNaO₁₀P₂
Compound Is Canonicalized：True
XLogP3-AA：325.03036405
Monoisotopic Mass：325.03036405
Complexity：293
Rotatable Bond Count：5
Hydrogen Bond Donor Count：8
Hydrogen Bond Acceptor Count：11
Topological Polar Surface Area：167
Heavy Atom Count：：18
Defined Atom Stereocenter Count：0
Undefined Atom Stereocenter Count：1
Defined Bond Stereocenter Count：0
Undefined Bond Stereocenter Count：0
Isotope Atom Count：0
Covalently-Bonded Unit Count：5
CACTVS Substructure Key Fingerprint：AAADceBiPCMAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAHggQCCAACADBgAQAAABAAhAAQAAAAIAAAAAAAAAAAIAAAAAAAAAAgAAAQAAEEAAAAAAgAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA==

9.Other Information

Merck: 14,229

Chemical Properties: White Crystalline Solid

Uses: A bisphosphonate used as a bone reabsoption inhibitor

Uses: dopamine receptor agonist, antiParkinsonian

Uses: Inhibits bone resorption and increases bone density.

Definition: ChEBI: A hydride that is the trihydrate of alendronate sodium

Brand name: Fosamax (Merck).

Usage: Alendronate sodium trihydrate is used as a bone resorption inhibitor, farnesyl diphosphate synthase inhibitor and CD45 protein tyrosine phosphatase inhibitor. A robust inhibitor of bone resorption that induces apoptosis. Alendronate inhibits the migration and invasion of PC-3 cells (sc-2220) by interfering with the mevalonate pathway. Additionally, Alendronate, Sodium Salt is an inhibitor of CD45RC and MMP.

View all

Originator: Adronat ,Neopharmed ,Italy

Manufacturing Process: 4-Amino-1-hydroxybutylidene-1,1-diphosphonic acid (ABDT).
Orthosphophorous acid (102.7 g; 1.25 moles) is introduced into a 2 liter-flask with condenser, stirrer and dropping funnel, placed on a thermostatized bath; the air is then removed with a nitrogen stream which is continued during all the reaction. The acid is melted by heating the bath to 95°C. When melting is complete, 4-aminobutyric acid (103.3; 1 mole) is added under stirring which is continued till obtaining a doughy fluid. Phosphorous trihalide (176 ml; 2 moles) is added dropwise causing the mixture to boil and evolution of gaseous hydrochloric acid which is damped by means of a suitable trap. The addition rate is adjusted so as to keep a constant reflux for about 60 minutes. When the addition is nearly over, the mixture swells, slowly hardening. Stirring is continued as long as possible, whereafter the mixture is heated for further 3 hours. Without cooling, but removing the bath, water (300 ml) is added, first slowly and then quickly. Heating and stirring are started again. Decolorizing charcoal is added and the mixture is boiled for about 5 minutes, then hotfiltered on paper and the filtrate is refluxed for 6 hours. After cooling is slowly poured in stirred methanol (1500 ml) causing thereby the separation of a white solid which collected and dried (161 g; 64.6%). The structure of ABDT is confirmed by IR spectrum, proton magnetic and nuclear magnetic resonance spectrum and elemental analysis.
The sodium salt of this acid may be prepared by adding of equivalent of sodium hydroxide.

View all

Therapeutic Function: Antiosteoporotic

General Description: Alendronate Sodium, an aminobisphosphonate compound, has been effectively used for the treatment of osteolysis, Paget′s disease and osteoporosis.

Storage Conditions: All chemicals were commercially purchased from Sigma Aldrich and used without further purification. Sodium carbonate, NaPreparation of alendronic acid monosodium salt; A mixture of 4-amino-butyric acid (10. Og, 0.097mol) and phosphorous acid (15.9g, 0.194mol) in acetonitrile (150ml) was heated at a temperature of 55-65°C and phosphorous trichloride (26.6g, 0.194mol) was added slowly under stirring. After completion of the addition, the reaction temperature was raised to 70-75Step 1: A mixture of 4-amino-butyric acid (10.0 g, 0.097 mol) and phosphorous acid (15.9 g, 0.194 mol) in acetonitrile (150 ml) was heated at a temperature of 55-65° C. and phosphorous trichloride (26.6 g, 0.194 mol) was added slowly under stirring. After completion of the addition, the reaction temperature was raised to 70-75° C. and the reaction continued for 6-9 hours at the same temperature. The reaction mixture was cooled to 60-65° C. and water (150 ml) was added slowly at the same temperature. The reaction temperature was then increased to 90-100° C. and maintained for the next 4-6 hours. The reaction mixture was then cooled to 55-65° C. and the reaction mixture pH was adjusted to 4.4-4.8 with sodium hydroxide solution. The reaction mixture was cooled to 25-35° C. and the aqueous layer containing the product was separated from the upper acetonitrile layer. The aqueous layer was cooled to and maintained at 0-5° C. for 3 hours. The solid product was separated by filtration and washed with water and finally with methanol to obtain sodium alendronate. The product was dried in a vacuum oven at 45-50° C. until loss on drying was less than 0.5percent w/w. Yield: 16 g (69.6percent). Appearance: almost white powder. Melting range: 234-238° C. (with decomposition).2.6 g (0.025 mol) of -γaminobutyric acid and 6.2 g (0.075mol) of phosphorous acid was added into 6.8 mL of MSA on stirring. Then 7.0 mL (0.075 mol) of phosphoryl chloride was added dropwise in ca. 15 min, and the contents of the flask were stirred at 75°C for 12 h. After cooling the mixture to 26°C, 19 mL (1.1 mol) of water was added and the mixture was stirred further at 105°C for 4 h. The pH was adjusted to 1.8 by adding ~12 mL of 50percent aqueous sodium hydroxide to the mixture. Then, the mixture was stirred at room temperature for 2 h and the precipitate was removed by filtration. The crude product was suspended in 50 mL ofwater and the mixture was stirred at 100°C for 1 h, then the pH was adjusted to 4, 5. After cooling the mixture to 26°C, the solid product was filtered off to give 5.0 g (60percent) of sodium alendronate trihydrate (8) in a purity of 97percent.3.8 mmol (1 equiv) of the respective carboxylic acid (658 mg 3-pyridylacetic acid hydrochloride for 1, 478 mg imidazol-1-yl-acetic acid for 2, 339 mg β-alanine for 3, 392 mg γ-aminobutyric acid for 4, 499 mg 6-aminohexanoic acid for 5) were added to 11.4 mmol (3 equiv) HTo a 250 ml reaction vessel equipped with a water condenser, 8.5 gm (0.1 mol) pyrrolidone, and 33.5 ml water was added under nitrogen atmosphere. Then, 17.2 gm (0.125 mol) PCl To a 250 ml reaction vessel equipped with water condenser, 8.5 gm (0.1 mol) pyrrolidone, and 33.5 ml water was added under nitrogen atmosphere. Then 17.2 gm (0.125 mol) PCl In a 250 reaction vessel equipped with water condenser, 8.5 gm (0.1 mol) pyrrolidone, 14 ml water and 11.5 gm methane sulphonic acid was added under nitrogen atmosphere. At room temperature 17.2 gm (11 ml, 0.125 mol) PClIn a 250 reaction vessel equipped with a water condenser, 8.5 gm (0.1 mol) pyrrolidone, 14 ml water, and 11.5 gm methane sulphonic acid were added under a nitrogen atmosphere. At room temperature, 17.2 gm (11 ml, 0.125 mol) PClExample 3 In a reaction vessel, 17.0 g(0.2 mol) pyrrolidone, 22 ml water and 23 gm methane sulphonic acid were taken and was heated to reflux (105 °C) for 9 hours or till the disappearance of pyrrolidone (monitored by TLC method). The mass was cooled to room temperature and PCl3 (17.5 ml, 0.199 mol) was added drop-wise while maintaining the temperature below 65 °C. Further the reaction was stirred at 60-65 °C for 30 minutes and then the temperature was raised to 110 °C, water was continuously distilled under vacuum. The mass was then cooled to 60 °C and added a further quantity of 90.39 gm (57.5 ml, 0.6565 mol) PCl3 was added drop-wise while maintaining the temperature below 60 °C followed by 25.5 ml of HEXAMPLE 3 In a reaction vessel, 17.0 g (0.2 mol) pyrrolidone, 22 ml water, and 23 gm methane sulphonic acid were mixed and then heated to reflux (i.e., 105° C.) for 9 hours or till the disappearance of pyrrolidone was observed (monitored by TLC method). The mass was then cooled to room temperature and PCl

View all

10. Toltal 314 Suppliers View more

High purity API Alendronate sodium Cas 121268-17-5 with high quality and best price

Wuhan Fortuna Chemical Co., Ltd.

^1YR

Tel: Update Time:2024/08/08

inquire

alendronate sodium trihydrate Cas 121268-17-5 from China

Hebei Crovell Biotech Co. Ltd

^1YR

Tel: Update Time:2024/11/15

inquire

Hebei Yanxi Chemical Co.,Ltd

^1YR

Tel: Update Time:2024/11/14

inquire

Baoji Guokang Healthchem co.,ltd

^1YR

Tel: Update Time:2024/11/15

inquire

Amitychem Corporation

^1YR

Tel: Update Time:2023/06/28

inquire

11. Related Questions

: How long should you take alendronate sodium tablets?There are some bisphosphonates that are given to treat the hypercalcemia associated with hypercalcemia of hyperparathyroidism. Alendronate is NOT one of those drugs, though it is in the bisphosphonate..; Can Alendronate Sodium Relieve Neuropathic Pain by Inhibiting Glial Cell Activation?Alendronate sodium (ALN) is a nitrogen-containing bisphosphonate commonly used to treat osteoporosis. There have been reports suggesting that ALN can alleviate pain, but its mechanism is not clear. Th..; What should we pay attention to when using Alendronate sodium?Alendronate sodium is an effective treatment for postmenopausal women with osteoporosis. This medication comes in tablet form and has the ability to inhibit the activity of bone cells. It is recognize..; What is alendronate sodium used for?Background and overview[1] Alendronate sodium is a third-generation bisphosphonate drug and is currently the first-line drug for the prevention and treatment of osteoporosis internationally. Studies h..

12. Realated Product Infomation